RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
Go back to RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study| REDHILL BIO SP ADS (NASDAQ: RDHL) | Delayed: 0.74 -0.13 (14.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.87 | 52 Week High | $16.54 | |||
| Open | $0.84 | 52 Week Low | $8.10 | |||
| Day High | $0.88 | P/E | N/A | |||
| Day Low | $0.72 | EPS | $0.00 | |||
| Volume | 1,438,049 | |||||
